Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 4/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4061216 | 0.88 | TSHR (0.50) | TSHRMMP8ANPEPDPP4 | |
| SCHEMBL2675825 | 0.81 | CCR1 (0.38) | TSHRMMP8CCR1ANPEPHDAC8 | |
| SCHEMBL2675864 | 0.81 | CCR1 (0.38) | TSHRMMP8CCR1ANPEPHDAC8 | |
| SCHEMBL2675868 | 0.80 | CCR1 (0.48) | MMP8CCR1ANPEPHDAC8 | |
| SCHEMBL2675827 | 0.80 | CCR1 (0.48) | MMP8CCR1ANPEPHDAC8 | |
| SCHEMBL6879395 | 0.69 | TSHR (0.67) | TSHRMMP8HDAC8 | |
| SCHEMBL4068030 | 0.68 | MMP2 (0.46) | MMP8CCR1ANPEP | |
| SCHEMBL4072351 | 0.68 | MMP1 (0.37) | TSHRMMP8CCR1ANPEP | |
| SCHEMBL8256096 | 0.68 | TSHR (1.00) | TSHRMMP8ANPEPHDAC8 | |
| SCHEMBL4072357 | 0.68 | CCR1 (0.46) | MMP8CCR1ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1404302-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ADSORBATES OF AMORPHOUS DRUG | PFIZER PROD INC (US) | 2010-11-03 | — | — | EP | claimed |
| US-20020198207-A1 | Novel Hexanoic acid derivatives | KATH JOHN CHARLES (US) | 2002-12-26 | — | — | US | claimed |
| EP-0966443-A1 | HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR | PFIZER INC. (US) | 1999-12-29 | — | — | EP | claimed |
| WO-1998038167-A1 | HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR | PFIZER INC. (US) | 1998-09-03 | — | — | WO | claimed |
| US-8257739-B2 | low-solubility drug (especially CCR-1 inhibitors) and a concentration-enhancing polymer; drug-rich regions are interspersed throughout drug-poor, polymer-rich regions; storage stability | BEND RESEARCH, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| EP-1404302-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ADSORBATES OF AMORPHOUS DRUG | PFIZER PROD INC (US) | 2010-11-03 | — | — | EP | disclosed |
| EP-1399190-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LOW-SOLUBILITY AND ACID-SENSITIVE DRUGS AND NEUTRALIZED ACIDIC POLYMERS | BEND RES INC (US) | 2010-09-08 | — | — | EP | disclosed |
| EP-2111856-A2 | Pharmaceutical compositions of semi-ordered drugs and polymers | Pfizer Products Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| EP-1401503-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A SOLID DISPERSION OF A POORLY-SOLUBLE DRUG AND A SOLUBILITY-ENHANCING POLYMER | PFIZER PROD INC (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20040156905-A1 | Pharmaceutical compositions of semi-ordered drugs and polymers | PFIZER INC. | 2004-08-12 | — | — | US | disclosed |
| US-20030104063-A1 | Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers | LONZA BEND INC. | 2003-06-05 | — | — | US | disclosed |
| US-20030072801-A1 | Pharmaceutical compositions comprising drug and concentration-enhancing polymers | PFIZER INC. | 2003-04-17 | — | — | US | disclosed |
| US-20030054038-A1 | Pharmaceutical compositions of drugs and neutralized acidic polymers | BEND RESEARCH, INC. | 2003-03-20 | — | — | US | disclosed |
| EP-1269994-A2 | Pharmaceutical compositions comprising drug and concentration-enhancing polymers | Pfizer Products Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020198207-A1 | Novel Hexanoic acid derivatives | KATH JOHN CHARLES (US) | 2002-12-26 | — | — | US | disclosed |
| EP-0966443-A1 | HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR | PFIZER INC. (US) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998038167-A1 | HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR | PFIZER INC. (US) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030072801-A1 | Pharmaceutical compositions comprising drug and concentration-enhancing polymers | ABCB1, ABCG2, CYP3A7 | TSHR 4833/4885MMP8 2526/4885CCR1 1504/4885 |
| US-20030104063-A1 | Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers | ABCG2, ABCB1, MATR3 | TSHR 4702/4885MMP8 2775/4885CCR1 3503/4885 |
| US-20030054038-A1 | Pharmaceutical compositions of drugs and neutralized acidic polymers | PDE7A, CA6, PDE9A | TSHR 3687/4885MMP8 1594/4885CCR1 1188/4885 |
| US-20040156905-A1 | Pharmaceutical compositions of semi-ordered drugs and polymers | ABCB1, ABCG2, PDE7A | TSHR 4366/4885MMP8 3620/4885CCR1 1295/4885 |
| US-20020198207-A1 | Novel Hexanoic acid derivatives | HCAR3, HCAR1, FFAR1 | TSHR 1211/4885MMP8 3590/4885CCR1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.